Is adaptive therapy natural?

article

Is adaptive therapy natural? is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1371/JOURNAL.PBIO.2007066
P932PMC publication ID6168119
P698PubMed publication ID30278037

P50authorAurélie TasiemskiQ30225261
François RenaudQ51281070
Beata UjvariQ56417092
Rodrigo HamedeQ57008026
Frédéric ThomasQ60584475
Robert GatenbyQ89150844
Guillaume M. CharrièreQ44626858
P2093author name stringEmmanuel Donnadieu
Joel Brown
Benjamin Roche
Pascal Pujol
Camille Jacqueline
P2860cites workThe CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsQ24631515
Evolutionary Ecology of Organs: A Missing Link in Cancer Development?Q26261170
The wound healing, chronic fibrosis, and cancer progression triadQ27014616
Cancer-related inflammationQ27860907
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healingQ28131793
Cancer immunoediting: from immunosurveillance to tumor escapeQ28212251
Life history trade-offs in cancer evolutionQ28657962
Evolved tumor suppression: why are we so good at not getting cancer?Q28681637
Evolutionary foundations for cancer biologyQ28709090
Evolutionary medicine: its scope, interest and potentialQ28715053
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progressionQ29614274
The immunobiology of cancer immunosurveillance and immunoeditingQ29616246
Cancer drug resistance: an evolving paradigmQ29616694
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumorsQ30505678
Aging, Cellular Senescence, and CancerQ34199776
The moulding of senescence by natural selectionQ34243235
Circumventing Cancer Drug Resistance in the Era of Personalized MedicineQ34274940
Cancer without disease.Q34301350
Drug resistance in cancer: an overview.Q34437369
Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.Q34610483
The seed and soil hypothesis revisited—The role of tumor‐stroma interactions in metastasis to different organsQ34784896
Adaptive therapy.Q34984307
A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models.Q51761333
Targeting the tumour stroma to improve cancer therapyQ52322982
Pseudoprogression and hyperprogression after checkpoint blockadeQ52630684
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphomaQ53253117
A causal mechanism for childhood acute lymphoblastic leukaemia.Q54203616
Cancer treatment: The killer withinQ56896941
The importance of cancer cells for animal evolutionary ecologyQ57049688
Depressed immune surveillance against cancer: role of deficient T cell: extracellular matrix interactionsQ72424888
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphomaQ80556384
Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunitiesQ91473881
Dual roles of immune cells and their factors in cancer development and progressionQ35022538
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escapeQ35300077
Evolutionary molecular medicineQ35560450
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking toleranceQ35690984
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in MiceQ36028047
Macrophages in Tumor Microenvironments and the Progression of TumorsQ36065902
Inclusive fitness effects can select for cancer suppression into old ageQ36088053
Preventive evolutionary medicine of cancersQ36595780
Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanismsQ37077231
Cancer: A disease at the crossroads of trade-offsQ37661123
Positive and negative influence of the matrix architecture on antitumor immune surveillanceQ38104594
Does the immune system naturally protect against cancer?Q38214640
Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndromeQ38667406
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Q39178061
Tuning cancer fate: the unremitting role of host immunity.Q39239026
The evolution of lifespan and age-dependent cancer riskQ39260251
Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease StateQ39308285
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and MetastasisQ40742367
Fever: is it beneficial?Q40810284
Cancer multidrug resistanceQ40827165
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth RateQ43715235
Breakthrough of the year 2013. Cancer immunotherapyQ43822796
Age-specific acceleration of cancerQ44169262
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancerQ46253252
Adaptive immunity maintains occult cancer in an equilibrium stateQ46891052
Spatial competition constrains resistance to targeted cancer therapy.Q47267135
Acquired resistance to immunotherapy and future challengesQ48235785
Cancer vaccine: learning lessons from immune checkpoint inhibitorsQ49260236
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue10
P407language of work or nameEnglishQ1860
P304page(s)e2007066
P577publication date2018-10-02
P1433published inPLOS BiologyQ1771695
P1476titleIs adaptive therapy natural?
P478volume16

Reverse relations

cites work (P2860)
Q91721567Can postfertile life stages evolve as an anticancer mechanism?
Q91592587Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor
Q91284351The evolution of resistance and tolerance as cancer defences

Search more.